
Intellia Therapeutics secures $70M Series B to accelerate CRISPR technology
CRISPR gene-editing companies in the biotech landscape like Intellia are continuing to pick up speed with more investments.
CRISPR gene-editing companies in the biotech landscape like Intellia are continuing to pick up speed with more investments.